FAQ

1. When was Crucell founded?

Crucell was founded in 2000 following the merger of IntroGene with U-Bysis.

 

2. When did Crucell become a listed company?

October 2000.

 

3. On which stock exchanges is Crucell traded?

Crucell is listed on both Euronext Amsterdam and NASDAQ exchanges under the ticker symbol CRXL, and on the SWX Swiss Exchange under ticker symbol CRX.

 

4. When does Crucell’s fiscal year end?

Crucell’s fiscal year ends on December 31st.

 

5. What is the date of your next results announcement?

Please refer to our Event Calendar page.

 

6. When is your Annual General Meeting (AGM) of shareholders?

Please refer to our Event Calendar page.

 

7. What accounting standards does Crucell report by?

Crucell reports under US GAAP accounting standards.

 

8. What is Crucell’s official accounting currency?

Crucell reports in Euro’s.

 

9. How many outstanding shares does Crucell have?

64,802,325 were outstanding on December 31, 2006.

 

10. I’m considering investing in Crucell. Where can I get financial information about the company?

You can receive up-to-date information on the Investors section of our website or by contacting Crucell’s Investor Relations department.

 

11. How can I buy Crucell shares?

Crucell shares are publicly traded and can be purchased through a securities broker.

 

12. Who is Crucell’s independent Auditor?

Deloitte, based in Eindhoven, The Netherlands.

 

13. Who are the analysts following Crucell?

Please refer to the Analyst Coverage section of this website.

 

14. What are Crucell's activities?

Crucell N.V. is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. For more information please refer to our About Us section.

 

15. What are Crucell's most important products?

Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology.

 

16. Why are financial details of license agreements often not disclosed?

Crucell only makes financial details of individual license agreements available in consultation with its licensees or partners. Financial details are often not disclosed for competitive reasons.